California Protons Cancer Therapy Center Invites Patients to Enroll in Breast Cancer Study and Clinical Trial
SAN DIEGO--(BUSINESS WIRE)--Apr 16, 2019--California Protons Cancer Therapy Center today announced two major efforts representing significant steps forward in breast cancer treatment research involving its noninvasive, targeted proton therapy. Current California Protons patients as of Feb. 4, 2019, are invited to enroll in the Proton Collaborative Group (PCG) Registry of more than 13,000 patients. Separately, the PCG BRE007-12 Partial Breast Irradiation in early stage breast cancer clinical trial will enroll around five to eight females per year.
The PCG Registry has been in existence since 2010 and is a prospective tracking study that allows for the collection and analysis of patient information to evaluate the disease process and treatment-related outcomes, thus defining strengths and weaknesses of proton radiation therapy. Qualified patients are invited to enroll in person at their first physician visit during treatment.
The primary objective of the PCG BRE007-12 Partial Breast Irradiation study is to determine freedom from ipsilateral breast recurrences in patients receiving partial breast proton radiation therapy limited to the region of the tumor at three years post-treatment. One of the goals of this study is to determine whether or not limiting radiation to just a portion of the breast is as effective as the traditional treatment of the entire breast. A number of trials have suggested that this “partial breast” approach is every bit as effective as treating the entire breast and may also be less toxic. Performing such partial breast treatments with protons can help to further reduce toxicity by taking advantage of the protons’ ability to be precisely conformed to the target area without giving “spillover” radiation to surrounding healthy tissue such as the lung and heart.
PCG has partnered with 11 proton treatment centers in the U.S., and the data has been used in close to 50 scientific manuscripts, posters and academic presentations to date. PCG research has been presented at 20 medical conferences and has been published in a number of peer-reviewed medical journals.
Both the Patient Registry and the Partial Breast Irradiation Trial are Institutional Review Board (IRB)-approved. These breast cancer trials supplement California Protons Cancer Therapy Center’s ongoing research projects with the University of California San Diego (UCSD) and the Radiation Therapy Oncology Group (RTOG) Foundation 3510 Phase III randomized trial of proton versus photon therapy for patients with nonmetastatic breast cancer receiving comprehensive nodal radiation.
About California Protons Cancer Therapy Center
California Protons’ intensity-modulated pencil beam scanning technology is a highly precise form of cancer radiation treatment that enables doctors to selectively target tumors with high-dose radiation while sparing healthy tissue. California Protons’ pencil beam scanning technology precisely delivers proton radiation treatment within 2 millimeters and with the utmost care. The treatment attacks tumors layer by layer and minimizes harmful exposure to surrounding healthy tissue and organs. This is important for breast cancer patients who may face the risk of secondary cancers, lung injuries and major cardiac events later in life due to previous radiation exposure. The reduction of radiation-related toxicity also increases the likelihood that patients can complete treatment with fewer interruptions or delays.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005223/en/
CONTACT: Karen Behrman
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: WOMEN HEALTH CLINICAL TRIALS ONCOLOGY RADIOLOGY CONSUMER
SOURCE: California Protons Cancer Therapy Center
Copyright Business Wire 2019.
PUB: 04/16/2019 11:00 AM/DISC: 04/16/2019 11:00 AM